Pangaea Express: Ontario Lists Inflectra @ 56% of Brand Price!

March 1, 2016

By Marla Weingarten

In the most recent Ontario Drug Benefit Formulary Summary of Changes, Hospira’s subsequent entry biologic (SEB), INFLECTRA (infliximab) received listing for the following indications:

  • Moderate to severe rheumatoid arthritis in patients who have severe active disease
  • For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease
  • For the treatment of psoriatic arthritis in patients who have severe active disease
  • For the treatment of severe plaque psoriasis

The listing will become effective Feb 25th 2016 and Inflectra will be reimbursed at a cost of $525.00 per 100mg/Vial Inj Pd-Vial Pk. This price of $525 is 56% of the price of the original biologic, Remicade. For more information, click here.

Currently, the price of Inflectra listed on RAMQ is $650 per 100mg/ vial. ( 70% of Brand ) As per the “most favoured nation” clause, Hospira will now need to lower its price to that of Ontario of $525.00.

Note: Health Canada had issued an NOC for Inflectra for 4 of the 9 indications granted to Remicade. Both RAMQ and the ODB are only reimbursing for these 4 indications.

Stay tuned for further details, and for more information contact Joe Knott, Managing Director, The Pangaea Group